Free quote the general11/14/2023 ![]() ![]() Shares of Aurinia have rallied 124% year to date against the industry’s 2.7% decline. ![]() If successful, AUR200 could become a valuable treatment option for certain autoimmune and kidney conditions. The company plans to submit an investigational new drug application to the FDA for the candidate in 2023. ![]() AUR200 is a recombinant Fc fusion protein. This increase reflects the expected growth in sales of Lupkynis.Īurinia’s pre-clinical development candidates include AUR200 and AUR300. It raised its projection to a range of $135-$155 million from the previously anticipated $120-$140 million. In May 2023, the company revised its net product revenue guidance for fiscal 2023. It generated a net product revenue of $34.4 million in the first quarter of 2023. Lupkynis, approved by the FDA in 2021, was the first drug to receive the federal agency’s approval for lupus nephritis. Its only marketed product is Lupkynis, an oral therapy approved to treat adult patients with active lupus nephritis. The company focuses on developing therapies for patients with autoimmune, kidney and rare diseases. Aurinia Pharmaceuticals ( AUPH Quick Quote AUPH - Free Report) rose almost 5.8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future.ĪUPH will consider a range of options, including a sale, merger, or other strategic transactions. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |